$33.40
-0.35-1.04%
At close: -
$33.40
0.000.00%
After Hours: Apr 25, 4:00 PM EDT
Comments
Loading...
AtriCure Analyst Ratings and Price Targets | NASDAQ:ATRC | Benzinga
AtriCure Inc has a consensus price target of $51.67 based on the ratings of 12 analysts. The high is $75 issued by SVB Leerink on May 4, 2022. The low is $40 issued by JP Morgan on October 30, 2024. The 3 most-recent analyst ratings were released by Citizens Capital Markets, Canaccord Genuity, and JP Morgan on April 2, 2025, March 28, 2025, and March 27, 2025, respectively. With an average price target of $52.67 between Citizens Capital Markets, Canaccord Genuity, and JP Morgan, there's an implied 57.68% upside for AtriCure Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Citizens Capital Markets
Canaccord Genuity
JP Morgan
Needham
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for AtriCure
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/02/2025 | Buy Now | 79.64% | Citizens Capital Markets | Daniel Stauder37% | $60 → $60 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/28/2025 | Buy Now | 55.69% | Canaccord Genuity | William Plovanic57% | $66 → $52 | Maintains | Buy | Get Alert |
| 03/27/2025 | Buy Now | 37.72% | JP Morgan | Lilia-Celine Lozada28% | $51 → $46 | Maintains | Overweight | Get Alert |
| 03/27/2025 | Buy Now | 52.69% | Needham | Mike Matson55% | $51 → $51 | Reiterates | Buy → Buy | Get Alert |
| 03/21/2025 | Buy Now | 52.69% | Needham | Mike Matson55% | $51 → $51 | Reiterates | Buy → Buy | Get Alert |
| 02/13/2025 | Buy Now | 34.73% | Oppenheimer | Suraj Kalia55% | $36 → $45 | Maintains | Outperform | Get Alert |
| 02/13/2025 | Buy Now | 49.7% | Piper Sandler | Matt O'Brien50% | $40 → $50 | Maintains | Overweight | Get Alert |
| 02/13/2025 | Buy Now | 79.64% | JMP Securities | Daniel Stauder37% | $60 → $60 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/13/2025 | Buy Now | 43.71% | Stifel | Rick Wise73% | $36 → $48 | Maintains | Buy | Get Alert |
| 02/13/2025 | Buy Now | 52.69% | Needham | Mike Matson55% | $51 → $51 | Reiterates | Buy → Buy | Get Alert |
| 02/13/2025 | Buy Now | 97.6% | Canaccord Genuity | William Plovanic57% | $61 → $66 | Maintains | Buy | Get Alert |
| 02/11/2025 | Buy Now | 52.69% | JP Morgan | Lilia-Celine Lozada28% | $40 → $51 | Maintains | Overweight | Get Alert |
| 02/10/2025 | Buy Now | 79.64% | JMP Securities | Daniel Stauder37% | $60 → $60 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 01/22/2025 | Buy Now | 52.69% | Needham | Mike Matson55% | $40 → $51 | Maintains | Buy | Get Alert |
| 01/13/2025 | Buy Now | 19.76% | Needham | Mike Matson55% | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
| 12/17/2024 | Buy Now | 19.76% | JP Morgan | Lilia-Celine Lozada28% | → $40 | Assumes | → Overweight | Get Alert |
| 12/09/2024 | Buy Now | 82.63% | Canaccord Genuity | William Plovanic57% | $53 → $61 | Maintains | Buy | Get Alert |
| 10/30/2024 | Buy Now | 58.68% | Canaccord Genuity | William Plovanic57% | $49 → $53 | Maintains | Buy | Get Alert |
| 10/30/2024 | Buy Now | 7.78% | Oppenheimer | Suraj Kalia55% | $32 → $36 | Maintains | Outperform | Get Alert |
| 10/30/2024 | Buy Now | 19.76% | JP Morgan | Robbie Marcus66% | $30 → $40 | Maintains | Overweight | Get Alert |
| 10/30/2024 | Buy Now | 19.76% | UBS | Danielle Antalffy61% | $35 → $40 | Maintains | Buy | Get Alert |
| 10/30/2024 | Buy Now | 19.76% | Needham | Mike Matson55% | $34 → $40 | Maintains | Buy | Get Alert |
| 07/31/2024 | Buy Now | 58.68% | BTIG | Marie Thibault62% | $58 → $53 | Maintains | Buy | Get Alert |
| 07/31/2024 | Buy Now | -10.18% | JP Morgan | Robbie Marcus66% | $34 → $30 | Maintains | Overweight | Get Alert |
| 07/31/2024 | Buy Now | -22.16% | Stifel | Rick Wise73% | $30 → $26 | Maintains | Buy | Get Alert |
| 07/31/2024 | Buy Now | 19.76% | Piper Sandler | Matt O'Brien50% | $65 → $40 | Maintains | Overweight | Get Alert |
| 07/31/2024 | Buy Now | 1.8% | Needham | Mike Matson55% | $40 → $34 | Maintains | Buy | Get Alert |
| 07/08/2024 | Buy Now | 19.76% | Needham | Mike Matson55% | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
| 05/02/2024 | Buy Now | 46.71% | Canaccord Genuity | William Plovanic57% | $57 → $49 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | 1.8% | JP Morgan | Robbie Marcus66% | $42 → $34 | Maintains | Overweight | Get Alert |
| 05/02/2024 | Buy Now | 19.76% | Needham | Mike Matson55% | $46 → $40 | Maintains | Buy | Get Alert |
| 04/23/2024 | Buy Now | -4.19% | Oppenheimer | Suraj Kalia55% | → $32 | Upgrade | Perform → Outperform | Get Alert |
| 04/10/2024 | Buy Now | 37.72% | Needham | Mike Matson55% | $46 → $46 | Reiterates | Buy → Buy | Get Alert |
| 02/16/2024 | Buy Now | 73.65% | UBS | Danielle Antalffy61% | $57 → $58 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | 25.75% | Stifel | Rick Wise73% | $50 → $42 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | 37.72% | Needham | Mike Matson55% | $44 → $46 | Maintains | Buy | Get Alert |
| 01/22/2024 | Buy Now | 70.66% | UBS | Danielle Antalffy61% | $56 → $57 | Maintains | Buy | Get Alert |
| 01/04/2024 | Buy Now | 31.74% | Needham | Mike Matson55% | $49 → $44 | Maintains | Buy | Get Alert |
| 11/29/2023 | Buy Now | 79.64% | JMP Securities | Daniel Stauder37% | → $60 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/29/2023 | Buy Now | 46.71% | Needham | Mike Matson55% | → $49 | Reiterates | Buy → Buy | Get Alert |
| 11/02/2023 | Buy Now | 49.7% | JP Morgan | Robbie Marcus66% | $60 → $50 | Maintains | Overweight | Get Alert |
| 11/02/2023 | Buy Now | 46.71% | Needham | Mike Matson55% | $68 → $49 | Maintains | Buy | Get Alert |
| 10/23/2023 | Buy Now | 79.64% | JMP Securities | Daniel Stauder37% | → $60 | Initiates | → Market Outperform | Get Alert |
| 09/29/2023 | Buy Now | 67.66% | UBS | Danielle Antalffy61% | → $56 | Initiates | → Buy | Get Alert |
| 07/26/2023 | Buy Now | 103.59% | Needham | Mike Matson55% | $60 → $68 | Maintains | Buy | Get Alert |
| 06/02/2023 | Buy Now | 79.64% | Needham | Mike Matson55% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/03/2023 | Buy Now | 79.64% | Needham | Mike Matson55% | $58 → $60 | Maintains | Buy | Get Alert |
| 04/17/2023 | Buy Now | 73.65% | Needham | Mike Matson55% | → $58 | Maintains | Buy | Get Alert |
| 02/22/2023 | Buy Now | 64.67% | BTIG | Marie Thibault62% | $65 → $55 | Maintains | Buy | Get Alert |
| 02/22/2023 | Buy Now | 43.71% | Stifel | Rick Wise73% | $55 → $48 | Maintains | Buy | Get Alert |
| 02/22/2023 | Buy Now | 121.56% | Canaccord Genuity | William Plovanic57% | $81 → $74 | Maintains | Buy | Get Alert |
| 02/22/2023 | Buy Now | 73.65% | Needham | Mike Matson55% | → $58 | Reiterates | → Buy | Get Alert |
| 02/06/2023 | Buy Now | 142.51% | Canaccord Genuity | William Plovanic57% | $67 → $81 | Maintains | Buy | Get Alert |
| 12/19/2022 | Buy Now | 73.65% | Needham | Mike Matson55% | $55 → $58 | Maintains | Buy | Get Alert |
| 11/02/2022 | Buy Now | 94.61% | Canaccord Genuity | William Plovanic57% | $72 → $65 | Maintains | Buy | Get Alert |
| 11/02/2022 | Buy Now | 64.67% | Needham | Mike Matson55% | $65 → $55 | Maintains | Buy | Get Alert |
| 10/17/2022 | Buy Now | 112.57% | BTIG | Marie Thibault62% | $75 → $71 | Maintains | Buy | Get Alert |
| 08/03/2022 | Buy Now | 64.67% | Piper Sandler | Matt O'Brien50% | $90 → $55 | Maintains | Overweight | Get Alert |
| 08/03/2022 | Buy Now | 94.61% | Needham | Mike Matson55% | $55 → $65 | Maintains | Buy | Get Alert |
| 07/18/2022 | Buy Now | 49.7% | Stifel | Rick Wise73% | $70 → $50 | Maintains | Buy | Get Alert |
| 06/28/2022 | Buy Now | 64.67% | Needham | Mike Matson55% | $67 → $55 | Maintains | Buy | Get Alert |
| 06/24/2022 | Buy Now | 124.55% | BTIG | Marie Thibault62% | $94 → $75 | Maintains | Buy | Get Alert |
| 05/04/2022 | Buy Now | 100.6% | Needham | Mike Matson55% | $79 → $67 | Maintains | Buy | Get Alert |
| 05/04/2022 | Buy Now | 124.55% | SVB Leerink | Danielle Antalffy61% | $95 → $75 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for AtriCure (ATRC) stock?
The latest price target for AtriCure (NASDAQ:ATRC) was reported by Citizens Capital Markets on April 2, 2025. The analyst firm set a price target for $60.00 expecting ATRC to rise to within 12 months (a possible 79.64% upside). 31 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AtriCure (ATRC)?
The latest analyst rating for AtriCure (NASDAQ:ATRC) was provided by Citizens Capital Markets, and AtriCure reiterated their market outperform rating.
When was the last upgrade for AtriCure (ATRC)?
The last upgrade for AtriCure Inc happened on April 23, 2024 when Oppenheimer raised their price target to $32. Oppenheimer previously had a perform for AtriCure Inc.
When was the last downgrade for AtriCure (ATRC)?
There is no last downgrade for AtriCure.
When is the next analyst rating going to be posted or updated for AtriCure (ATRC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AtriCure, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AtriCure was filed on April 2, 2025 so you should expect the next rating to be made available sometime around April 2, 2026.
Is the Analyst Rating AtriCure (ATRC) correct?
While ratings are subjective and will change, the latest AtriCure (ATRC) rating was a reiterated with a price target of $60.00 to $60.00. The current price AtriCure (ATRC) is trading at is $33.40, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
